<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5791">
  <stage>Registered</stage>
  <submitdate>1/02/2016</submitdate>
  <approvaldate>1/02/2016</approvaldate>
  <nctid>NCT02672852</nctid>
  <trial_identification>
    <studytitle>BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment</studytitle>
    <scientifictitle>BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-005102-38</secondaryid>
    <secondaryid>M15-992</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABBV-066
Treatment: drugs - Placebo

Experimental: ABBV-066 - 

Placebo Comparator: Placebo - 


Treatment: drugs: ABBV-066
ABBV-066 administered by subcutaneous injection

Treatment: drugs: Placebo
Placebo for ABBV-066 administered by subcutaneous injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Achievement of &gt;= 90% reduction from baseline Psoriasis Area and Severity Index (PASI) score (PASI90) at week 16</outcome>
      <timepoint>week 16</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Achievement of an static Physician Global Assessment (sPGA) score of clear or almost clear at week 16</outcome>
      <timepoint>Week 16</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of 100% reduction from baseline PASI score (PASI100) at week 16</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of PASI 90 at Week 52</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of PASI 100 at Week 52</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of a 75% reduction from baseline PASI score (PASI 75) at week 16</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of an sPGA score of clear(0) at Week 16</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of a Dermatology Life Quality Index (DLQI) score of 0 or 1 at Week 16</outcome>
      <timepoint>Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of an sPGA score of clear (0) or almost clear (1) at Week 52</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of PASI 75 at Week 52</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Male or female patients. Woman of childbearing potential must be ready and willing to
             use highly effective methods of birth control per ICH M3 (R2) that result in a low
             failure rate of less than 1 percent per year when used consistently and correctly.

          -  Age &gt;=18 years at screening

          -  Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) at
             least 6 months before the first administration of study drug. Duration of diagnosis
             may be reported by the patient.

          -  Have stable moderate to severe chronic plaque psoriasis with or without psoriatic
             arthritis at both Screening and Baseline (Randomization); Have an involved body
             surface area (BSA) &gt;= 10% and Have a Psoriasis Area and Severity Index (PASI) &gt;= 12
             and Have a static Physician Global Assessment (sPGA) score of &gt; = 3.

          -  Must be a candidate for systemic therapy or phototherapy for psoriasis treatment, as
             assessed by the investigator

          -  Signed and dated written informed consent prior to admission to the study and
             performance of any study procedures in accordance with GCP and local legislation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Patients with nonplaque forms of psoriasis (including guttate, erythrodermic, or
             pustular); current drug-induced psoriasis (including a new onset of psoriasis or an
             exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium);
             active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that
             might confound trial evaluations according to the investigators judgment.

          -  Previous exposure to ABBV-066

          -  Currently enrolled in another investigational study or less than 30 days (from
             screening) since completing another investigational study

          -  Use of any restricted medication as noted or any drug considered likely to interfere
             with the safe conduct of the study.

          -  Major surgery performed within 12 weeks prior to randomization or planned within 12
             months after screening (e.g. hip replacement, removal aneurysm, stomach ligation,).

          -  Known chronic or relevant acute infections such as active tuberculosis, HIV, or viral
             hepatitis

          -  Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal cell carcinoma or squamous cell
             carcinoma of the skin or in situ carcinoma of uterine cervix

          -  Evidence of a current or previous disease (including chronic alcohol or drug abuse),
             medical condition other than psoriasis, surgical procedure (i.e., organ transplant),
             medical examination finding (including vital signs and ECG), or laboratory value at
             the screening visit outside the reference range that in the opinion of the
             Investigator, is clinically significant and would make the study participant unable to
             adhere to the protocol or to complete the trial, compromise the safety of the patient,
             or compromise the quality of the data.

          -  History of allergy/hypersensitivity to a systemically administered biologic agent or
             its excipients

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial

          -  Previous enrolment in this trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>29/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>3/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,VIC,WA</recruitmentstate>
    <hospital>1311.4.61001 Boehringer Ingelheim Investigational Site - Phillip</hospital>
    <hospital>1311.4.61003 Boehringer Ingelheim Investigational Site - Liverpool</hospital>
    <hospital>1311.4.61004 Boehringer Ingelheim Investigational Site - East Melbourne</hospital>
    <hospital>1311.4.61002 Boehringer Ingelheim Investigational Site - Fremantle</hospital>
    <postcode> - Phillip</postcode>
    <postcode> - Liverpool</postcode>
    <postcode> - East Melbourne</postcode>
    <postcode> - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Li√®ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Nachod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Pardubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Quimper cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Blankenfeld-Mahlow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuppertal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi, Nagoya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka, Kurume</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tochigi, Shimotsuke</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo, Itabashi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo, Shinagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gwangju</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Pusan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seongnam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Boehringer Ingelheim</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a confirmatory, multicentre, randomized, double-blind, placebo controlled, 104 week
      study with a 88 week treatment period and a 16 week follow-up period evaluating the efficacy
      and safety of BI 655066 / ABBV-066 (risankizumab) to support Registration for the treatment
      of moderate to severe chronic plaque psoriasis in adult patients. This study will also look
      at the maintenance of response following randomly withdrawing treatment from those patients
      responding to treatment at week 28, as well as the response to re-treatment for patients who
      relapse. This study will also assess PK and emergence of anti-drug antibodies as well as the
      influence of study treatment on disease specific markers. In a subset of psoriasis patients
      with concomitant psoriatic arthritis, the signs and symptoms of psoriatic arthritis will be
      evaluated to assess improvement.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02672852</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>